Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III
Jane Robertson(Cancer Research UK), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), N. Botwood(AstraZeneca (United Kingdom)), Mace L. Rothenberg(Vanderbilt University)
Cited by 42
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
|Journal of Clinical Oncology|2000|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
|Annals of Oncology|1996|569